. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: Transplant Cell Ther. 2021 Nov 12;28(2):83.e1–83.e9. doi: 10.1016/j.jtct.2021.10.022

Table 5.

Univariate survival outcomes in patients receiving VCD and VRD induction, stratified by eGFR. Probabilities with 95% confidence intervals are shown

	VRD, eGFR≥60 (n=614)	VRD, eGFR<60 (n=241)	VCD, eGFR≥60 (n=98)	VCD, eGFR<60 (n=105)	p-value

PFS (%)					0.021
2-year	73 (68–77)	71 (64–78)	57 (46–67)	64 (53–74)	0.033
5-year	41 (33–48)	39 (27–51)	28 (17–40)	39 (25–53)	0.342

OS (%)					0.053
2-year	92 (89–95)	93 (89–96)	90 (83–95)	85 (76–92)	0.250
5-year	78 (72–84)	84 (76–90)	61 (48–73)	60 (44–75)	0.003

Table Abbreviations: OS: overall survival, PFS: progression free survival, VCD: bortezomib, cyclophosphamide and dexamethasone VRD: bortezomib, lenalidomide and dexamethasone.